Viking Therapeutics Inc (VKTX)
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic and endocrine disorders. Its pipeline includes VK2809, an orally available and tissue- and receptor-subtype selective thyroid hormone receptor beta agonist being studied in Phase IIb trials for biopsy-confirmed non-alcoholic steatohepatitis and NAFLD. The company is also developing VK5211, an oral non-steroidal selective androgen receptor modulator in Phase II trials for recovery after non-elective hip fracture surgery, along with VK0612 for metabolic disorders and anemia. Additional programs include VK2735, a dual GLP-1 agonist in Phase 1 SAD/MAD testing, and VK0214, a TRß agonist being evaluated for X-linked adrenoleukodystrophy. Viking Therapeutics was incorporated in 2012 and is headquartered in San Diego, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-VKTX
|
$37.28
|
0.3% Upside
|
Fair
|
$92.58
|
148.9% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
July 29, 2026
|
-9.2x
|
8.6x
|
—
|
4.224 B
|
3.723 B
|
0.0%
|
97.6%
|
19.8
|
—
|
72.1%
|
